Hospital perspective of shortages casts pharma earnings in bad light

Editor Ron Shinkman at sister publication FierceHealthFinance looks at drug shortages from the hospital exec's perspective and doesn't especially like what he sees. He finds that some shortages are caused by factory shutdowns. But unlike most other businesses in which shutdowns can lead to devastating write-offs, he instead finds companies revising operating and net income upward. Among his examples: Daiichi Sankyo's ($4568) American Regent, Hospira ($HSP), Boehringer Ingelheim's Bedford Labs and Bristol-Myers Squibb ($BMY). Editorial

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.